Licensing status

Publication and contact information




Mouse and nonhuman primate studies identified a humanized antihepcidin antibody that could help treat anemia of inflammation. Erythropoiesis-stimulating agents (ESAs) can help treat anemia, but inflammation-induced hepcidin can lower the efficacy of ESAs by sequestering iron. In a mouse model of anemia of inflammation with human hepcidin expression, an ESA plus a humanized, antihepcidin antibody increased iron levels and hemoglobin production in red blood cells compared with an ESA alone. In nonhuman primates, the antihepcidin antibody increased serum iron levels compared with saline. Next steps could include evaluating the antihepcidin antibody in additional animal anemia models.
Noxxon Pharma AG's hepcidin inhibitor, NOX-H94, is in Phase II testing to treat anemia.
At least two other companies have hepcidin inhibitors or antibodies in Phase I testing or earlier to treat anemia.

SciBX 6(36); doi:10.1038/scibx.2013.995
Published online Sept. 19, 2013

Patent and licensing status unavailable

Cooke, K.S. et al. Blood; published online Aug. 14, 2013;
Contact: Barbra J. Sasu, Amgen Inc., Thousand Oaks, Calif.